Renovorx, INC

RenovoRx, Inc. has received an additional 180-day period from Nasdaq to regain compliance with the minimum bid price requirement for continued listing.

RenovoRx, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of directors, approval of an incentive plan amendment, and ratification of its independent auditor.

RenovoRx announced its full year 2025 financial results, reporting $1.1 million in RenovoCath revenue and progress in its Phase III TIGeR-PaC trial, alongside a strengthened balance sheet.

RenovoRx, Inc. formally appointed Dr. Ramtin Agah as Executive Chairman, effective February 27, 2026, alongside his Chief Medical Officer role, with a new compensation package.

RenovoRx, Inc. announced an oversubscribed $10 million private placement of common stock and warrants, aiming to accelerate commercialization and advance its Phase III clinical trial.

RenovoRx, Inc. announced the appointment of Mark Voll, an experienced public company executive, as its new Chief Financial Officer, effective February 4, 2026, following the voluntary resignation of Ronald B. Kocak as Principal Accounting Officer.

RenovoRx announces significant revenue acceleration in Q1 2026, driven by increased commercial adoption of its RenovoCath device, while its TIGeR-PaC trial nears enrollment completion.

RenovoRx reported increased revenue from RenovoCath sales in Q3 2025, but faces significant net losses and substantial doubt about its ability to continue as a going concern without additional funding.

RenovoRx, Inc. announced significant revenue growth from RenovoCath sales and positive progress in its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.

RenovoRx reports its Q1 2025 financial results, highlighting initial revenue generation from RenovoCath commercial sales and progress in its Phase III TIGeR-PaC clinical trial.

RenovoRx has issued a common stock purchase warrant to Medical Murray, its contract manufacturing partner, tied to production milestones, as the company explores commercial opportunities for its RenovoCath device.

RenovoRx reported a net loss of $3.465 million for the first six months of 2024, while also highlighting progress in its clinical trials and exploring new commercial opportunities.

RenovoRx, Inc. filed an amendment to its 2025 Annual Report to update risk factor disclosures and provide additional details regarding the remediation of previously identified material weaknesses in internal control over financial reporting.

RenovoRx, a life sciences company, reported $1.1 million in RenovoCath sales for 2025 and continued progress in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.

RenovoRx, a life sciences company, announces initial revenue from RenovoCath sales and details its plans for revenue growth and clinical trial progress in 2025.

RenovoRx's 2023 annual report highlights the company's focus on its TAMP platform, clinical trial progress, and financial position as it advances its lead product candidate, RenovoGem.

Director Una S. Ryan acquired shares of RenovoRx common stock through distributions from investment funds.

RenovoRx Chief Financial Officer Mark Voll reported the acquisition of 25,000 common shares and the vesting of 8,823 restricted stock units.

RenovoRx, Inc. CEO Shaun Bagai has been granted nearly 1 million stock options with a four-year vesting schedule starting January 2026.

RenovoRx Chief Financial Officer Mark Voll received a grant of 80,000 restricted stock units as compensation for past and future services.

RenovoRx, Inc. has issued 128,550 stock options to its Chief Clinical Officer, Leesa Gentry, as part of a long-term incentive and retention strategy.

RenovoRx, Inc. has granted Chief Medical Officer Ramtin Agah options to purchase 621,727 shares at an exercise price of $0.98.

RenovoRx, Inc. is holding its 2025 Annual Meeting of Stockholders to elect directors, approve amendments to its equity incentive plan, and ratify the appointment of its independent auditor.

RenovoRx will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, to elect directors and conduct other business.

AIGH Capital Management LLC and associated entities report beneficial ownership of 9.8% of Renovorx, Inc. common stock as of March 31, 2026.

AIGH Capital Management LLC and Orin Hirschman have reported a 7.1% beneficial ownership stake in Renovorx, Inc. common stock.

AWM Investment Company, Inc. filed an amended Schedule 13G, disclosing its beneficial ownership of 2.4% of RenovoRx, Inc.'s common stock as of September 30, 2025.

AIGH Capital Management LLC and Orin Hirschman have disclosed a 7.1% beneficial ownership stake in Renovorx, Inc., holding 2,615,193 shares of common stock.

AWM Investment Company, Inc. has increased its beneficial ownership in RenovoRx, Inc. to 5.1% of the common stock, holding 1,870,225 shares.

AIGH Capital Management, LLC and its managing member Orin Hirschman have disclosed a passive 9.5% beneficial ownership stake in Renovorx, Inc. as of March 31, 2025.